{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:55:02Z","timestamp":1793346902431,"version":"4.5.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The extracellular domain of tumor necrosis factor receptors (TNFR) generally require assembly into a homotrimeric quaternary structure as a prerequisite for initiation of signaling via the cytoplasmic domains. TNF receptor homotrimers are natively activated by similarly homo-trimerized TNF ligands, but can also be activated by synthetic agonists including engineered antibodies and Fc-ligand fusion proteins. A large body of literature from pre-clinical models supports the hypothesis that synthetic agonists targeting a diverse range of TNF receptors (including 4-1BB, CD40, OX40, GITR, DR5, TNFRSF25, HVEM, LT\u03b2R, CD27, and CD30) could amplify immune responses to provide clinical benefit in patients with infectious diseases or cancer. Unfortunately, however, the pre-clinical attributes of synthetic TNF receptor agonists have not translated well in human clinical studies, and have instead raised fundamental questions regarding the intrinsic biology of TNF receptors. Clinical observations of bell-shaped dose response curves have led some to hypothesize that TNF receptor overstimulation is possible and can lead to anergy and\/or activation induced cell death of target cells. Safety issues including liver toxicity and cytokine release syndrome have also been observed in humans, raising questions as to whether those toxicities are driven by overstimulation of the targeted TNF receptor, a non-TNF receptor related attribute of the synthetic agonist, or both. Together, these clinical findings have limited the development of many TNF receptor agonists, and may have prevented generation of clinical data which reflects the full potential of TNF receptor agonism. A number of recent studies have provided structural insights into how different TNF receptor agonists bind and cluster TNF receptors, and these insights aid in deconvoluting the intrinsic biology of TNF receptors with the mechanistic underpinnings of synthetic TNF receptor agonist therapeutics.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1236332","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T04:35:15Z","timestamp":1695184515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists"],"prefix":"10.3389","volume":"14","author":[{"given":"George","family":"Fromm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"de Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor H.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2051-1426-2-7","article-title":"Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy","volume":"2","author":"Schaer","year":"2014","journal-title":"J Immunother Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1184","article-title":"Signalling pathways of the TNF superfamily: a double-edged sword","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3930","article-title":"Clinical targeting of the TNF and TNFR superfamilies","volume":"12","author":"Croft","year":"2013","journal-title":"Nat Rev Drug Discovery"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030275","article-title":"Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis","volume":"7","author":"Aaltonen","year":"2012","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"vii5","DOI":"10.1093\/rheumatology\/key059","article-title":"20 years of experience with tumour necrosis factor inhibitors: what have we learned","volume":"57","author":"Caporali","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.01.004","article-title":"4-1BB, and CD40 as targets for cancer immunotherapy","volume":"25","author":"Moran","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020299","article-title":"The implementation of TNFRSF co-stimulatory domains in CAR-T cells for optimal functional activity","volume":"14","author":"He","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aao4910","article-title":"Structural principles of tumor necrosis factor superfamily signaling","volume":"11","author":"Vanamee","year":"2018","journal-title":"Sci Signal"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2010.12.004","article-title":"Decoy strategies: the structure of TL1A:DcR3 complex","volume":"19","author":"Zhan","year":"2011","journal-title":"Structure"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.814905","article-title":"Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling","volume":"293","author":"Bitra","year":"2018","journal-title":"J Biol Chem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80207-5","article-title":"Triggering cell death: the crystal structure of Apo2L\/TRAIL in a complex with death receptor 5","volume":"4","author":"Hymowitz","year":"1999","journal-title":"Mol Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.12.6510","article-title":"Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses","volume":"161","author":"Gramaglia","year":"1998","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.569684","article-title":"The diversity and similarity of transmembrane trimerization of TNF receptors","volume":"8","author":"Zhao","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aax5647","article-title":"Single-molecule imaging reveals the oligomeric state of functional TNFalpha-induced plasma membrane TNFR1 clusters in cells","volume":"13","author":"Karathanasis","year":"2020","journal-title":"Sci Signal"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2677","article-title":"Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40","volume":"23","author":"Messenheimer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0292","article-title":"Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis","volume":"5","author":"Shrimali","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05673-2","article-title":"Reducing affinity as a strategy to boost immunomodulatory antibody agonism","volume":"614","author":"Yu","year":"2023","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ccell.2018.02.009","article-title":"Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies","volume":"33","author":"Yu","year":"2018","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.03.040","article-title":"Shining a LIGHT on myeloid cell targeted immunotherapy","volume":"187","author":"Shuptrine","year":"2023","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s42003-021-02309-5","article-title":"TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity","volume":"4","author":"Yu","year":"2021","journal-title":"Commun Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2015.109","article-title":"Principles of antibody-mediated TNF receptor activation","volume":"22","author":"Wajant","year":"2015","journal-title":"Cell Death Differ"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132687","article-title":"Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies","volume":"211","author":"Madireddi","year":"2014","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1605","article-title":"E2 interaction and dimerization in the crystal structure of TRAF6","volume":"16","author":"Yin","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1922","article-title":"Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in patients with advanced cancer","volume":"24","author":"Segal","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-1132","article-title":"Multimeric anti-DR5 igM agonist antibody IGM-8444 is a potent inducer of cancer cell apoptosis and synergizes with chemotherapy and BCL-2 inhibitor ABT-199","volume":"20","author":"Wang","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12342","article-title":"FcgammaR requirements leading to successful immunotherapy","volume":"268","author":"Dahal","year":"2015","journal-title":"Immunol Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1029","article-title":"CD137 (4-1BB)-based cancer immunotherapy on its 25th anniversary","volume":"13","author":"Melero","year":"2023","journal-title":"Cancer Discovery"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.5544","article-title":"Phase 1 dose escalation study of SL-172154 (SIRP\u03b1-Fc-CD40L) in platinum-resistant ovarian cancer","author":"Lakhani","year":"2023","journal-title":"Am Soc Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abp9229","article-title":"A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors","volume":"15","author":"Melero","year":"2023","journal-title":"Sci Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0493","article-title":"CD40 enhances type I interferon responses downstream of CD47 blockade, bridging innate and adaptive immunity","volume":"8","author":"de Silva","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s40425-018-0454-3","article-title":"Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy","volume":"6","author":"Fromm","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002015","article-title":"Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors","volume":"9","author":"Luke","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1147467","article-title":"Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives","volume":"14","author":"Dadas","year":"2023","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2101175","article-title":"LIGHT (TNFSF14) costimulation enhances myeloid cell activation and antitumor immunity in the setting of PD-1\/PD-L1 and TIGIT checkpoint blockade","volume":"209","author":"Yoo","year":"2022","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s40425-019-0671-4","article-title":"HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcgammaR-binding functionality","volume":"7","author":"Richards","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168947","article-title":"The role of fc receptors on the effectiveness of therapeutic monoclonal antibodies","volume":"22","author":"Gogesch","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1398-6","article-title":"FcgammaRIotaIotaB controls the potency of agonistic anti-TNFR mAbs","volume":"62","author":"White","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101135","article-title":"Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody","volume":"187","author":"White","year":"2011","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.immuni.2005.05.010","article-title":"FcgammaRIV: a novel FcR with distinct IgG subclass specificity","volume":"23","author":"Nimmerjahn","year":"2005","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1319502110","article-title":"Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo","volume":"110","author":"Li","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0526","article-title":"An integrative approach to inform optimal administration of OX40 agonist antibodies in patients with advanced solid tumors","volume":"25","author":"Wang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.3027","article-title":"The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600)","volume":"35","author":"El-Khoueiry","year":"2017","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2527","article-title":"A phase 1 study to assess safety, pharmacokinetics (PK) and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors","author":"Calvo","year":"2019","journal-title":"Am Soc Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10637-022-01319-2","article-title":"A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors","volume":"41","author":"Moreno","year":"2023","journal-title":"Invest New Drugs"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.003","article-title":"Development of an integrated method to quantify receptor occupancy for agonist immunotherapeutics that stimulate target cells to migrate from the peripheral blood","author":"Gonzalez","year":"2021","journal-title":"Soc Immunotherapy Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.494","article-title":"Phase 1 dose escalation of an agonist redirected checkpoint (ARC) fusion protein, SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas (NCT03894618)","author":"Johnson","year":"2022","journal-title":"Soc Immunotherapy Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4174","article-title":"OX40 is a potent immune-stimulating target in late-stage cancer patients","volume":"73","author":"Curti","year":"2013","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200597","article-title":"T cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccination","volume":"189","author":"Schreiber","year":"2012","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0608","article-title":"Epitope and fc-mediated cross-linking, but not high affinity, are critical for antitumor activity of CD137 agonist antibody with reduced liver toxicity","volume":"19","author":"Ho","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padron","year":"2022","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2355","article-title":"Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study","volume":"21","author":"Johnson","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1810566115","article-title":"Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity","volume":"115","author":"Knorr","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1345","article-title":"Preclinical characterization and phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors","volume":"12","author":"Muik","year":"2022","journal-title":"Cancer Discovery"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100285","article-title":"First-in-human study to evaluate the safety and clinical activity of FS222, a tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors","author":"De Velasco Oria","year":"2022","journal-title":"Eur Soc Med Oncol - IO"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/LBA2019.2","article-title":"Phase 1 dose escalation study of PRS-343, a HER2\/4-1BB bispecific molecule, in patients with HER2+ Malignancies","author":"Piha-Paul","year":"2021","journal-title":"Am Assoc Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1810566115","article-title":"First-in-human trial to evaluate safety, PK\/PD and initial clinical activity of NM21-1480, an affinity-balanced PD-L1x4-1BBxHSA trispecificantibody: Results of Phase 1 dose escalation","author":"Hong","year":"2022","journal-title":"Soc Immunotherapy Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.615141","article-title":"Receptor oligomerization and its relevance for signaling by receptors of the tumor necrosis factor receptor superfamily","volume":"8","author":"Kucka","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01749.x","article-title":"Biased signalling and allosteric machines: new vistas and challenges for drug discovery","volume":"165","author":"Kenakin","year":"2012","journal-title":"Br J Pharmacol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01247-1","article-title":"Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study","volume":"40","author":"LoRusso","year":"2022","journal-title":"Invest New Drugs"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157011","article-title":"CD19 4-1BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-cell-engaging bispecific antibody glofitamab in relapsed or refractory B-cell non-hodgkin lymphoma","author":"Hutchins","year":"2022","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6484","article-title":"OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor","volume":"68","author":"Gough","year":"2008","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502659","article-title":"Immunotherapy expands and maintains the function of high-affinity tumor-infiltrating CD8 T cells in situ","volume":"197","author":"Moran","year":"2016","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1236332\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T04:35:22Z","timestamp":1695184522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1236332\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2023.1236332"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1236332","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"article-number":"1236332"}}